

HSHS St. Vincent Hospital Regional Cancer Center – Adult Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
S1314	SWOG-L	NCT02177695	Bladder	A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
NHLBI-MDS	ECOG-A	NCT02775383	Blood Disorders-Other	The National Myelodysplastic Syndromes (MDS) Study
PNH Registry M07-001	DRUG CO	NCT01374360	Blood Disorders-Other	PNH Registry
A071102	ALLIANCE	NCT02152982	Brain	A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
A221101	ALLIANCE	NCT01781468	Brain	A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
A221102	ALLIANCE	NCT01573442	Breast- Miscellaneous	Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias
SC-1603	ACCRU	NCT02961790	Breast- Miscellaneous	A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes
SCUSF 1102	SCUSF	NCT01789684	Breast- Miscellaneous	A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
BR002	NRG	NCT02364557	Breast-Advanced (Metastatic/Recurrent)	A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
E2112	ECOG	NCT02115282	Breast-Advanced (Metastatic/Recurrent)	A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
R1119	RTOG	NCT01622868	Breast-Advanced (Metastatic/Recurrent)	Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG

HSHS St. Vincent Hospital Regional Cancer Center – Adult Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
RU0112011	ACCRU	NCT02037529	Breast-Advanced (Metastatic/Recurrent)	A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A011202	ALLIANCE	NCT01901094	Breast-Early Stage (Adjuvant)	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A011401	ALLIANCE	NCT02750826	Breast-Early Stage (Adjuvant)	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
A011502	ALLIANCE	NCT02927249	Breast-Early Stage (Adjuvant)	A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node-positive HER2 negative breast cancer: The ABC trial
B-51	NSABP	NCT01872975	Breast-Early Stage (Adjuvant)	A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
B-55	NSABP	NCT02032823	Breast-Early Stage (Adjuvant)	A Randomized, Double-blind, Parallel group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
BR003	NRG	NCT02488967	Breast-Early Stage (Adjuvant)	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer
E1Z11	ECOG	NCT01824836	Breast-Early Stage (Adjuvant)	A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

HSHS St. Vincent Hospital Regional Cancer Center – Adult Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
EA1131	ECOG-A	NCT02445391	Breast-Early Stage (Adjuvant)	A Randomized Phase III Post-Operative Trial of PlatinumBased Chemotherapy Vs. Capecitabine in Patients withResidual Triple-Negative Basal-Like Breast Cancerfollowing Neoadjuvant Chemotherapy
PrE0109/AFT-05	PrECOG	NCT02513394	Breast-Early Stage (Adjuvant)	PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
S1207	SWOG-L	NCT01674140	Breast-Early Stage (Adjuvant)	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.
DCP-001	DCP	Not Available	Cancer Control-Other	Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
N0392	NCCTG		Cancer Control-Other	Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials
URCC 14040	URCC	NCT02613364	Cancer Control-Other	A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors
URCC13059	URCC	NCT02054741	Cancer Control-Other	A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults
0724	RTOG	NCT00980954	Cervical	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

HSHS St. Vincent Hospital Regional Cancer Center – Adult Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
G0263	GOG	NCT01101451	Cervical	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
C-13	NSABP-F	NCT02664077	Colon	A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
E7208	ECOG	NCT01079780	Colon and Rectal	A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
GLNE010	ALLIANCE	NCT01511653	Colon and Rectal	Validation and Comparison of Biomarkers for the Early Detection of Colorectal Adenocarcinoma
MPR-1	NSABP-F	NCT01793805	Colon and Rectal	NSABP Patient Registry and Biospecimen Profiling Repository
RU0214071	ACCRU	NCT02368886	Colon and Rectal	Regorafenib Dose Optimization Study (ReDOS); A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer (mCRC)
S0820	SWOG-L	NCT01349881	Colon and Rectal	A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
0920	RTOG	NCT00956007	Head and Neck	A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
R1008	RTOG	NCT01220583	Head and Neck	A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

HSHS St. Vincent Hospital Regional Cancer Center – Adult Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
R1216	RTOG	NCT01810913	Head and Neck	Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
E1910	ECOG	NCT02003222	Leukemia-Acute Lymphocytic Leukemia (ALL)	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
S1318	SWOG-L	NCT02143414	Leukemia-Acute Lymphocytic Leukemia (ALL)	A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
E2906	ECOG	NCT01041703	Leukemia-Acute Myelogenous Leukemia (AML)	Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age > 60 Years)
MDS/AML Registry	DRUG CO	NCT01688011	Leukemia-Acute Myelogenous Leukemia (AML)	The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
PCYC-1134M-CA	DRUG CO	NCT02582879	Leukemia-Chronic Lymphocytic Leukemia (CLL)	informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia
A081105	ALLIANCE	NCT02193282	Lung- Non-Small Cell Lung Cancer	Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
A151216	ALLIANCE	NCT02194738	Lung- Non-Small Cell Lung Cancer	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

HSHS St. Vincent Hospital Regional Cancer Center – Adult Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
E4512	ECOG-A	NCT02201992	Lung- Non-Small Cell Lung Cancer	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
EA5142	ECOG-A	NCT02595944	Lung- Non-Small Cell Lung Cancer	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Merck MK-3475-407	DRUG CO	NCT02775435	Lung- Non-Small Cell Lung Cancer	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
R1306	RTOG	NCT01822496	Lung- Non-Small Cell Lung Cancer	A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
S1400	SWOG-L	NCT02154490	Lung- Non-Small Cell Lung Cancer	A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
30610	CALGB	NCT00632853	Lung- Small Cell Lung Cancer	Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide
EA6134	ECOG-A	NCT02224781	Melanoma	A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
S1404	SWOG-L	NCT02506153	Melanoma	A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
EAQ152	ECOG-A	NCT02823652	Multiple Disease Sites	COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling
EAY131	ECOG-A	NCT02465060	Multiple Disease Sites	Molecular Analysis for Therapy Choice (MATCH)

HSHS St. Vincent Hospital Regional Cancer Center – Adult Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
A061202	ALLIANCE	NCT02004275	Multiple Myeloma	A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
E1A11	ECOG	NCT01863550	Multiple Myeloma	Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma
E3A06	ECOG	NCT01169337	Multiple Myeloma	Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
NSMM-5001	DRUG CO	NCT02761187	Multiple Myeloma	A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study
S1211	SWOG-L	NCT01668719	Multiple Myeloma	A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
G0225	GOG	NCT00719303	Ovarian	Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival
GY004	NRG	NCT02446600	Ovarian	A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
0848	RTOG	NCT01013649	Pancreas	A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
0924	RTOG	NCT01368588	Prostate	Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

HSHS St. Vincent Hospital Regional Cancer Center – Adult Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
S1216	SWOG-L	NCT01809691	Prostate	A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
39039039STM4001	ACCRU	NCT02555878	Symptom/Side Effect Management	Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
AFT-28	AFT	NCT02744092	Symptom/Side Effect Management	Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS TRIAL)
0238	GOG	NCT00492778	Uterine-Endometrial	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
G0286B	GOG	NCT02065687	Uterine-Endometrial	A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer